Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multicenter, two-part, randomized, parallel group, placebo and sitagliptin-controlled study to evaluate the safety and efficacy of GSK256073 administered once or twice daily for 12 weeks in subjects with type 2 diabetes mellitus who are being treated with metformin.

Trial Profile

A multicenter, two-part, randomized, parallel group, placebo and sitagliptin-controlled study to evaluate the safety and efficacy of GSK256073 administered once or twice daily for 12 weeks in subjects with type 2 diabetes mellitus who are being treated with metformin.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 08 Oct 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs GSK 256073 (Primary) ; Sitagliptin
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions; Biomarker; Therapeutic Use
  • Sponsors GlaxoSmithKline

Most Recent Events

  • 10 May 2012 Status changed from recruiting to active, no longer recruiting as reported by United Kingdom Clinical Research Network record.
  • 18 Nov 2011 Additional location (Scotland) added as reported by United Kingdom Clinical Research Network record.
  • 16 Nov 2011 Planned patient number changed from 270 to 300 as reported by EudraCT.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top